Multinational drug company Mylan has said it will invest USD one billion in the next 5-6 years on Capex in India, given the importance of the country's position in world pharma supply-chain, and pitched for the government incentivising research and development activities. Mylan Global President and Executive Director Rajiv Malik said the company had been investing close to about USD 400 million or USD 450 million towards Capex every year and half of it in India.
Mylan Laboratories has dropped its pursuit to patent a novel process for preparation of Sildenafil Citrate, the active ingredient in Pfizer's erectile dysfunction drug Viagra.